» Articles » PMID: 30425761

Pneumonia: Walking Pneumonia Can Cripple the Susceptible

Overview
Journal J Clin Med Res
Specialty General Medicine
Date 2018 Nov 15
PMID 30425761
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: pneumonia (MPP), or "walking pneumonia," is an atypical mild disease with varied clinical findings. Specifically, diagnosis is often controversial and understanding of disease presentation is limited. The goal of the study was to evaluate presentation, clinical associations and outcomes of MPP patients admitted to an inner-city hospital.

Methods: This was a retrospective analysis of adult patients diagnosed with MPP from January 2010 to January 2017. Primary outcomes were need for intensive care unit (ICU) care, ICU and hospital length of stay (LOS), presence of shock and need for mechanical ventilation (MV). Predictors of mortality were analyzed.

Results: Of the 203 patients analyzed, 16 (8%) died. Relative to survivors, non-survivors were older (65 ± 21 versus 53 ± 18, P = 0.009) and less frequently had obstructive airway disease (OAD; P = 0.003). Non-survivors also had significantly higher serum levels of lactic dehydrogenase (LDH), blood urea nitrogen (BUN), creatinine, transaminases and troponins. Finally, non-survivors more commonly exhibited shock, need for MV and bilateral lung infiltrates. There were no group differences in patient comorbidities, symptoms, antibiotic use or LOS. Predictors of mortality included age, OAD, low CD4 T-cell counts in human immunodeficiency virus-infected patients and elevated serum levels of LDH, creatinine, BUN, leukocytes, transaminases and troponins.

Conclusion: Despite the availability of appropriate antibiotics, MPP incurs significant mortality and morbidity. Our study indicated that the recommended treatment includes prompt serological diagnosis, aggressive supportive care and presumptive antibiotics, especially in patients with poor prognosis.

Citing Articles

Mycoplasma pneumoniae Infection With Cavitated Lung Lesions: A Case Report.

Campos A, Goncalves F, Costa M, Alves G, Cotter J Cureus. 2022; 14(11):e31572.

PMID: 36540488 PMC: 9757645. DOI: 10.7759/cureus.31572.


[Clinical features of children with pneumonia and peripheral lymphocytopenia].

Peng L, Zhong L, Huang Z, Li Y, Zhang B Zhongguo Dang Dai Er Ke Za Zhi. 2021; 23(1):74-77.

PMID: 33476541 PMC: 7818155.


Lipid moieties of lipoproteins are the causative factor of vaccine-enhanced disease.

Mara A, Gavitt T, Tulman E, Geary S, Szczepanek S NPJ Vaccines. 2020; 5(1):31.

PMID: 32284882 PMC: 7142147. DOI: 10.1038/s41541-020-0181-x.


Effect of pidotimod combined with azithromycin on children with mycoplasma pneumonia and the expression levels of IL-10 and G-CSF in serum.

Shi H, Lan L, Lv X, Sun L Exp Ther Med. 2019; 18(3):1800-1806.

PMID: 31410140 PMC: 6676206. DOI: 10.3892/etm.2019.7725.

References
1.
Narita M . Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia. J Infect Chemother. 2010; 16(3):162-9. DOI: 10.1007/s10156-010-0044-x. View

2.
John S, Ramanathan J, Swischuk L . Spectrum of clinical and radiographic findings in pediatric mycoplasma pneumonia. Radiographics. 2001; 21(1):121-31. DOI: 10.1148/radiographics.21.1.g01ja10121. View

3.
Medina J, Coalson J, Brooks E, Winter V, Chaparro A, Principe M . Mycoplasma pneumoniae CARDS toxin induces pulmonary eosinophilic and lymphocytic inflammation. Am J Respir Cell Mol Biol. 2012; 46(6):815-22. PMC: 3380286. DOI: 10.1165/rcmb.2011-0135OC. View

4.
Miyashita N, Ouchi K, Kawasaki K, Oda K, Kawai Y, Shimizu H . Mycoplasma pneumoniae pneumonia in the elderly. Med Sci Monit. 2008; 14(8):CR387-91. View

5.
Marrie T . Mycoplasma pneumoniae pneumonia requiring hospitalization, with emphasis on infection in the elderly. Arch Intern Med. 1993; 153(4):488-94. View